Progyny, Inc. (NASDAQ:PGNY – Get Free Report) Chairman David J. Schlanger sold 2,597 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $37.65, for a total value of $97,777.05. Following the completion of the sale, the chairman now directly owns 86,312 shares in the company, valued at approximately $3,249,646.80. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Progyny Price Performance
NASDAQ PGNY opened at $37.99 on Thursday. The business has a 50 day moving average price of $37.92 and a 200 day moving average price of $35.60. The company has a market capitalization of $3.67 billion, a P/E ratio of 61.27, a PEG ratio of 1.53 and a beta of 1.48. Progyny, Inc. has a 1-year low of $29.44 and a 1-year high of $44.95.
Progyny (NASDAQ:PGNY – Get Free Report) last posted its earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.04. Progyny had a return on equity of 12.64% and a net margin of 5.70%. The firm had revenue of $269.94 million for the quarter, compared to analyst estimates of $274.08 million. During the same quarter in the prior year, the company earned $0.03 EPS. Progyny’s revenue was up 26.0% on a year-over-year basis. On average, research analysts expect that Progyny, Inc. will post 0.7 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Progyny
Wall Street Analyst Weigh In
PGNY has been the topic of a number of recent analyst reports. KeyCorp dropped their price objective on shares of Progyny from $45.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 28th. Truist Financial decreased their target price on Progyny from $47.00 to $46.00 and set a “buy” rating for the company in a research note on Wednesday, February 28th. SVB Leerink began coverage on shares of Progyny in a research note on Monday, February 26th. They issued an “outperform” rating and a $49.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $48.00 price objective on shares of Progyny in a research report on Wednesday, February 28th. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of Progyny in a research note on Monday, February 26th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Progyny has a consensus rating of “Buy” and an average price target of $48.30.
Check Out Our Latest Stock Analysis on Progyny
About Progyny
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
See Also
- Five stocks we like better than Progyny
- What is a buyback in stocks? A comprehensive guide for investors
- Krispy Kreme’s Sweet Deal: McDonald’s Partnership Sparks Growth?
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
- What does consumer price index measure?
- 7 Stocks That Will Drive the Weight Loss Drugs Market
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.